🇺🇸 FDA
Company

Keros

Keros Therapeutics

KROS pharma USA

Quick answer

Keros is a pharma company (KROS) headquartered in LEXINGTON, MA, USA with 2 tracked pipeline programs.

Pipeline (2)

project

Dose A KER-012

Pulmonary Arterial Hypertension

Phase 2 · mab · completed

1 trials project

KER-047

Iron Deficiency Anemia

Phase 2 · small_molecule · terminated

1 trials

Patents (8)

patent

US 12404313

GDNF fusion polypeptides and methods of use thereof

Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12364737

Activin receptor type IIA variants and methods of use thereof

Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12350313

Activin receptor type IIa variants and methods of use thereof

Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12331124

ALK2 antibodies and methods of use thereof

Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12269858

Activin receptor type IIB variants and methods of use thereof

Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12071438

Crystal forms of an ALK2 inhibitor

Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11912750

GDNF fusion polypeptides and methods of use thereof

Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11884715

Activin receptor type IIB variants and methods of use thereof

Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)